Vimarsana
Biggest News Aggregation in the World

Page 9 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annu - Vimarsana News

MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annu

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M...

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K - Vimarsana News

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 ... | May 11, 2023

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors - Vimarsana News

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

AGENUS INC. : Stock Market News and Information | AGEN| US00847G7051 - Vimarsana News

AGENUS INC. : Stock Market News and Information | AGEN| US00847G7051

AGENUS INC. : News, information and stories for AGENUS INC. | Nasdaq: AGEN | Nasdaq

Taylor Highlights Safety and Efficacy of IgG4 Monoclonal Antibody IO-108 in Advanced Solid Tumors - Vimarsana News

Taylor Highlights Safety and Efficacy of IgG4 Monoclonal Antibody IO-108 in Advanced Solid Tumors

Matthew H. Taylor, MD, discusses findings from a phase 1 study of IO-108 in advanced solid tumors, which was presented during the 2023 AACR Annual Meeting.